{"name":"Dyne Therapeutics","slug":"dyne-therapeutics","ticker":"","exchange":"","domain":"dyne.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":398333000,"netIncome":-446214000,"cash":893369000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DYNE-101","genericName":"DYNE-101","slug":"dyne-101","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"DYNE-101","genericName":"DYNE-101","slug":"dyne-101","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPRjQtdzgwTFprdFo5M25Ecmxtbkx5THIzblVtZ05JWEZlLTBvMGRGeU5lNmdmRFVrRVNsYmtwY3pFUkRiQXhZVjVXZHlITVFBekQtSjlPQ1VKSU5nSFczNFA0S1pkTklBWFA2aGE0T0NmSWxsZDZwNVNXcFptSTdaemVITzZWYTFvWTBnRTNfME04enZGNGQ2U01YcFZuZjgtZHpKUzVmYl9ZS2I2TlVIWmNsQkRubDZCSWx1RQ?oc=5","date":"2026-02-26","type":"pipeline","source":"Fierce Pharma","summary":"Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies - Fierce Pharma","headline":"Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTWVWbFF2eC1pNjhlUXZ0bWZlVXFITDFJcjMtaTBUdkN2NEFWU0NxbWtRZkJHb2p1MG9SU2JVM2lTWEREVFZ2a0dfNUw4Q04wNjZQdzFIMnZoMUo5UU52dVRQLU9vMThpREttdW82YXZ5bmRvbkhzdUdNZTBMZzZqa2VQd0R1N2dSRTVONVZRUm03OUlHVmt4MEVNS2MwR2ZmY3Q1cUswOUNrcUNyTnRzdEVkX0dsQzlLODk3SFlxblRzS09uNjA2bzY0UGlIRVRu?oc=5","date":"2025-12-09","type":"trial","source":"TechStock²","summary":"Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets - TechStock²","headline":"Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets - ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOd1VoWUNkREdPREhSdlUyREtlekNsYzhUNzhjdy1DQ2RPLV9tTUZkR1h4Z0xNcVZpb3NWM0hxbXBWQjM0TEhrTmlOMGNRb1laQnBJR285dHRteldLcUc2X08zMHIyUzE4ektVX2FZY2tvQ2R1WWNfUFF3UVZKNEp6S2NrZHdIQWtRdEE1OUFWOVBTTjhWU1dfalBn?oc=5","date":"2025-12-08","type":"regulatory","source":"Fierce Biotech","summary":"Dyne readies FDA push after DMD exon 51 med excels in trial - Fierce Biotech","headline":"Dyne readies FDA push after DMD exon 51 med excels in trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zT182RG1QUVlIXzVjQllsN19qVkdDZ1dhYWFBd1RsdGN4TGR3ZkgyOEV2UWRpaUZ3bGYzZjA0NlRNRG5vNDVjYlR1OFFmYVl1akNV?oc=5","date":"2025-12-08","type":"trial","source":"FirstWord Pharma","summary":"Dyne readout lays groundwork for planned 2026 Duchenne filing - FirstWord Pharma","headline":"Dyne readout lays groundwork for planned 2026 Duchenne filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOaGdaaWVkNVJZWXpKb3I5dldhSG9VNmEtODRPZWZEcnZ5WVRPWDFCRUhiSFBxaXl5ZkV2MGlTUlZTTjliYW1ucFRCcnlwNWt0NlZlRUt4c0lMWnV3d2ZwdWt5cHNtcm5HcnpDTFlSWlNzbHBkVTQ2V0VZR0dqN0hvb0lQRU1pYVBod0dSM1d1U1ZXT0NpcWR4VA?oc=5","date":"2025-11-21","type":"pipeline","source":"The Motley Fool","summary":"Why Dyne Therapeutics Stock Was Crushing it This Week - The Motley Fool","headline":"Why Dyne Therapeutics Stock Was Crushing it This Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOaE02cjVia1hoa0RGX1otZ1lRajd4R1E3ZzQ5NHRlOHVfbDV3VkpCdUxpREpfSmkwMkNmU1U3aWI3M1RYUFZOS0YtNzZaNU1lSDU2YzFMQU83Z3dyNUljTzF3V2lWd3dsSVZlOVJyRjRKYmJabnpSRHFIUmF1SzJRTC15WVJzZ2RMSkluRUVyUElwZWlBN1l2TWhCMnBIdFZlTEUwUTRZMFNfRnRQYkV2U25ZbHhQREtBQjhOOG5oaDhySU9XZUdZenhTMFFzclE?oc=5","date":"2025-11-17","type":"pipeline","source":"Benzinga","summary":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga","headline":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbmpyV2tCTUZ1NHlET3ktejIwXzBCMXZaOXhRdy1KbVNEcGdWYVEzaHNiNElDWnNQTFVrY09yUmJuMkRydlZVOW9vSHFkQ3RBbUtXRFBrcE04UkhRQ3JSWGJNOFd4dlJIdFYyMXZobEpUenZYWWlReEE0bU1mVGp0bVItSVlsb0dXUGF6VVFvMDNNVnJsMXQ5Q1NhdE5ZVjVfLWRmcXpLRWNlWVlZcy0ydlZjQkwzdUQt?oc=5","date":"2025-10-31","type":"pipeline","source":"Business Wire","summary":"Circle Pharma Appoints Rob Lauzen as Chief Financial Officer - Business Wire","headline":"Circle Pharma Appoints Rob Lauzen as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBvOVhydngzZDVfY2lNSFFoTHVtT3h1MTJnUlJxZnRCbFRVZG1oTzcwMFlHRFpISWxFY05qN2FHSDRBNWtvV0t2MU9xMC1VMnluT2R3?oc=5","date":"2025-06-17","type":"regulatory","source":"FirstWord Pharma","summary":"Dyne's stock dips as accelerated approval plans for dystrophy drug get delayed - FirstWord Pharma","headline":"Dyne's stock dips as accelerated approval plans for dystrophy drug get delayed","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-17","type":"pipeline","source":"simplywall.st","summary":"Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbU5NMmF3WDZicXV0NEs3OWQtZmVONS1ORnBPNHVLSTF6V00wNURRbkd0WmFNSkQ1R05XZUotWmlpQ1puWTh4ck82MWRJMXNVRlVhYWNUNjdEZTROVUJKcS0zREdJeHl3LXNvU3lzTlpvbm9HQ2xRelA1MXVxaDBjLWRSV3VSOFdQYzc0WEJVLTU5eGNxOVFWYWdta25ZdjlrZDdaSWJxNWhzR2FUaVlMM1RPaw?oc=5","date":"2025-02-17","type":"pipeline","source":"BioSpace","summary":"Opinion: Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1 - BioSpace","headline":"Opinion: Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPWlg5ZzNQX0RXVlBKd3MwNGJLRkdqeTAxUkx2c0p4cXFiU01ReVZqZlBBcDAtbktOXzJnRDVCRjkzYUZ4YThhbUdTcXdNV3FyQWVIc2E2QkVzYzUyUmladWdVMWZ0Yk5hVndFczhVOW1POUhUQnlwOHJaUkhaU2E2M0N4VDg2WHhSSlJKem5UeHE4V1E4YWhfSHZBcGVVck5aUGdrMHBmTFk3NFY0Zl80ci11VQ?oc=5","date":"2024-01-26","type":"pipeline","source":"Bloomberg.com","summary":"Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest - Bloomberg.com","headline":"Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":398333000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-446214000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":893369000,"cashHistory":[],"totalAssets":1186958000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}